Clinical Study "Common" Name (formal title)	Number of enrollees	Funding source (pharma/NIH)	Year complete	Primary publication	Full study treatment protocol
Comparing safety and efficacy of bevacizumab, ranibizumab and ranibizumab biosimilar in retinopathy of prematurity	n = 139 eyes (70 babies) Bevacizumab: 68 eyes (34 babies) Ranibizumab: 31 eyes (16 babies) Razumab™ 40 eyes (20 babies)	Not disclosed	2023	Maitra P, Jaju S, Agrawal KU, et al. Comparing safety and efficacy of bevacizumab, ranibizumab and ranibizumab biosimilar in retinopathy of prematurity. Eye (Lond). Published online February 27, 2025:1-6. https://www.nature.com/articles/s41433-025-03735-z	The choice of anti-VEGF was by patient’s preference. When injection criteria were met, bilateral injections if needed were given under strict aseptic precautions under topical anaesthesia with the same intravitreal agent on the same day with sterile precautions and protocols being followed between each eye: 0.5 mg of Bevacizumab (Avastin) 0.2 mg of Ranibizumab (Accentrix, Novartis, India) or 0.2 mg of Razumab™ (Razumab, Intas Pharmaceuticals, India) After the injection the eye was kept patched for 4 hours and topical antibiotic was prescribed for 1 week.  Babies were followed up as per protocol and retreatment with laser or repeat anti-VEGF was done in case of reactivation and surgery in case of progression to traction. Outcome measures include need for retreatment, proportion of eyes achieving vascularization up to ora and adverse events